Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Clinical trial NCT07523555 · RECRUITING

Trial details

NCT number: NCT07523555
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia T-lymphoblastic Lymphoma Peripheral T-cell Lymphoma

Start date: 2026-03-02
Primary completion: 2027-03-14
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.